This clinical practice guideline focuses on the early detection of colorectal cancer and the management of polyps found during colorectal cancer screening among those at average risk, as well as the workup and diagnosis of colorectal cancer. The guideline discusses the optimal strategies for population-level early detection of colorectal cancer in high-incidence and resource-constrained settings, the optimal reflex testing strategy for people with positive screening results, the optimal strategy for people with premalignant polyps or other abnormal screening results, and the optimal methods for diagnosing patients who have signs and symptoms of early colorectal cancer. Recommendations are resource-stratified and are tailored to basic, limited, enhanced and maximal resource settings.
We've listed guidelines under your selection of "Continuum of care". The most recent guidelines are first.
This is a clinical practice guideline on the screening for cervical cancer. The guideline examines the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and related benefits and harms of different screening strategies. Specific strategies discussed include screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years, screening every 3 years with cervical cytology alone, screening every 5 years with high-risk human papillomavirus (HPV) testing alone, and screening every 5 years with high-risk HPV testing in combination with cytology (co-testing) in women aged 30 to 65 years.
This is a clinical practice guideline for the management of epithelial precancerous conditions and lesions in the stomach. The guideline specifically addresses the diagnostic assessment, treatment and surveillance of individuals with atrophic gastritis, intestinal metaplasia, and dysplasia of the stomach. Topics discussed include endoscopic diagnosis, biopsies and histology, noninvasive assessment, management, Helicobacter pylori treatment, follow-up, and the cost-effectiveness of surveillance and screening.
This is a clinical practice guideline for men and women with inherited polyposis syndromes. The guideline examines the identification and management of familial adenomatosis polyposis (FAP), attenuated FAP, MutY homologue-associated polyposis (MAP), and polyposis without an identified genotype. Extraintestinal manifestations included in the adenomatous polyposis syndromes are also discussed.
This is a clinical practice guideline for adult patients who may be at risk for developing breast cancer. The guideline examines breast cancer screening for this patient population at different levels of risk. Different screening options such as mammography, ultrasound, magnetic resonance imaging, and tomosynthesis are discussed.
This is a clinical practice guideline for women with uterine cancer. The guideline provides recommendations for the screening and prevention of uterine cancer in the general population and in high risk groups, as well as for the pathological work-up, management, and follow-up of patients with uterine cancer. Specific conditions discussed include endometrioid endometrial cancer, as well as non-endometrioid cancers such as uterine serous carcinoma, uterine clear cell carcinoma, and uterine carcinosarcoma.
This is a clinical practice guideline for patients with epithelial ovarian-type cancers (e.g. ovary, fallopian tube or peritoneal origin) and borderline tumours. This guideline addresses epithelial cancers of varying histological subtypes. The guideline covers the full continuum of care including screening and prevention, diagnosis, treatment options such as surgery, systemic therapy and chemotherapy, follow-up, as well as management of recurrent disease. The guideline also highlights the support needs for women with ovarian cancer.
This is a clinical practice guideline for the management of patients with advanced breast cancer (ABC), including those with locally advanced breast cancer (LABC) and metastatic breast cancer (MBC). The guideline provides recommendations for the management of these patients, and specifically discusses the use of chemotherapy, management of bone metastases, management of cancer related fatigue, as well as supportive and palliative care.
This is a clinical practice guideline for patients with small cell lung cancer. The guideline examines the diagnosis, staging, prognostic factors, treatment, and surveillance of these patients. Treatment options discussed include systemic therapy, radiotherapy, and surgical resection. Systemic therapy is further examined in elderly patients, and as a second-line (and beyond) treatment. Radiotherapy treatments considered include thoracic radiotherapy, prophylactic cranial irradiation, and palliative radiotherapy.
This is a clinical practice guideline for patients presenting to primary care services with signs and/or symptoms of lung cancer. The guideline examines the referral process for this patient population. Topics of interest include factors that have been shown to increase the risk of lung cancer, symptoms that should be present in a person before referral, indications for chest computed tomography (CT) scan, and follow-up to diagnostic investigations.